SKYRIZI

Abbvie Corporation🇨🇦 Health Canada

Approval Id: fe14df49379dff9b
Drug Approval Canada Name: SKYRIZI
Product Name: SKYRIZI
Status: Marketed
Status Date: 2022-06-01
Original Market Date: 2022-06-01
Din: 02519291
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 84:06.28
Atc Original: L04AC18 RIZANKIZUMAB
Atc Name: l 04 ac 18
Aig Number: 0161390002
Company Name: Abbvie Corporation
Company Address: 8401 Trans-Canada Highway, Saint-Laurent, Quebec, Canada, H4S 1Z1
Company Detail Path: /organization/abbvie-corporation

RISANKIZUMAB

150 MG / 1 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

fe14df49379dff9b

Type

Standard